Researchers at the Indiana University School of Medicine, Eskenazi Health, Regenstrief Institute and other partners have demonstrated the feasibility of conducting dementia prevention trials among older adults with limited formal education, a group at heightened risk for Alzheimer’s disease and related dementias.

The MINDSpeed trial, a randomized study, tested whether a diet rich in polyphenols, which are plant-based compounds found in foods like nuts and berries, and online speed-of-processing cognitive training could improve cognition in older adults with 12 or fewer years of education.

This paper introduces a novel methodology for analysing and optimising the matching process between angel investors and startup companies by integrating artificial intelligence (AI) and game-theoretic models. Leveraging the natural language processing capabilities of AI engines such as Gemini and ChatGPT 4, we extract and analyse historical investment patterns to identify critical qualitative and quantitative criteria influencing investment decisions. These criteria are further refined through R programming simulations, optimising cutoff values using the Youden index to balance sensitivity and specificity in predicting successful matches. Our findings demonstrate the effectiveness of a hybrid framework that combines qualitative preferences with quantitative metrics, offering a comprehensive tool for enhancing strategic investment decisions. This study represents the first attempt to apply AI technologies systematically to the investor-startup matching process, contributing practical insights for investors, entrepreneurs, and intermediaries in navigating the early-stage investment landscape. The proposed approach not only improves matching efficiency but also supports the creation of stronger, more aligned partnerships within the entrepreneurial ecosystem.

Lipid nanoparticles (LNPs) have emerged as versatile and widely utilized delivery systems in both academic research and industrial applications, offering immense potential beyond liver-targeted and infectious disease treatments. Despite their success, a significant limitation of LNPs is their inherent liver tropism following systemic administration. This liver-centric accumulation represents a key bottleneck, restricting the broader therapeutic applications of LNP-based delivery systems. In a recent review, the authors explore strategies to overcome this challenge by modulating LNP composition—including ionizable lipids, helper lipids, cholesterol, and other critical components—to achieve extrahepatic targeting. The authors further discuss recent advancements in surface modification techniques designed to redirect LNPs to organs beyond the liver. Additionally, the authors highlight recent progress in local delivery approaches, which offer a direct and effective alternative for achieving extrahepatic delivery. By providing a comprehensive overview of current strategies and limitations, the authors aim to guide future research efforts toward fully realizing the therapeutic potential of LNP-based delivery systems.